Are you Dr. Bastian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-8410
Summary
- Dr. Boris Bastian, MD is a pathologist in New York, New York. He is currently licensed to practice medicine in New York and California. He is affiliated with University of California San Francisco Medical Center at Mount Zion and is a Professor of Dermatology at UCSF.
Education & Training
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2001 - 2025
NY State Medical License 2010 - 2015
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors: New York Metro Area Castle Connolly, 2012
- America's Top Doctors for Cancer Castle Connolly, 2005-2009, 2011
Publications & Presentations
PubMed
- 1162 citationsCNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA SequencingEric Talevich, A. Hunter Shain, Thomas Botton, Boris C. Bastian
Plos Computational Biology. 2016-04-21 - 674 citationsThe Genetic Evolution of Melanoma from Precursor LesionsA. Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, Aravindhan Sriharan, Eric Talevich
The New England Journal of Medicine. 2015-11-11 - 504 citationsOvercoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh CellsAlexander Roesch, Adina Vultur, Ivan Bogeski, Huan Wang, Katharina M. Zimmermann
Cancer Cell. 2013-06-10
Press Mentions
Evolution of Melanoma Reveals Opportunities for InterventionJuly 9th, 2018
Correcting a Blind SpotJune 30th, 2018
American Skin Association Announces Abby S. And Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma Skin Cancer ResearchApril 17th, 2018- Join now to see all
Grant Support
- The KIT Signaling Pathway As A Therapeutic Target In MelanomaNational Cancer Institute2011–2012
- The GNAQ Pathway As A Therapeutic Target In Uveal MelanomaNational Cancer Institute2010–2012
- The GNAQ Pathway As A Therapeutic Target In Uveal MelanomaNational Cancer Institute2011
- Biomarker Discovery For The Classification Of MelanomaNational Cancer Institute2010–2011
- Biomarker Discovery For The Classification Of MelanomaNational Cancer Institute2008–2011
- Genetic Expression Of Lentigo Malignant Melanoma - UCSF ConsortiumNational Cancer Institute2007–2009
- Genomic Analysis Of Squamous Cell CarcinomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2003–2007
- Genetic Expression Of Lentigo Malignant Melanoma, Proj. 2 - UCSF ConsortiumNational Cancer Institute2005–2006
- Classification Of Ambiguous Melanocytic TumorsNational Cancer Institute2002–2005
